Expert Insights in Hemophilia Gene Therapy for Bleeding Disorders Awareness Month

Article

In observance of Bleeding Disorders Awareness Month, held annually in March, catch up on some of the latest expert insights in gene therapies for hemophilia, which is among the most common of these disorders.

In recent months, CGTLive has interviewed multiple experts about the various gene therapies currently in development for the treatment of hemophilia A and hemophilia B, which are among the most commonly occurring bleeding disorders.

For Bleeding Disorders Awareness Month, observed annually in the month of March by the patient and clinician communities, the CGTLive team has gathered some of our latest interviews on hemophilia gene therapies below to offer expert insight on the therapeutic progress being made for these rare disorders.

Those featured include:

  • Adam Cuker, MD, associate professor of medicine at the University of Pennsylvania
  • Steven Pipe, MD, professor of pediatric hematology/oncology at CS Mott Children’s Hospital
  • Brent Warner, president of gene therapy at Poseida Therapeutics
  • Rigoberto Garcia, MPH, executive director of the Hemophilia Foundation Southern California

Click the respective slides below to watch each expert interview.


—————————————————

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Related Content
© 2025 MJH Life Sciences

All rights reserved.